A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants

Trial Profile

A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs NGM 313 (Primary)
  • Indications Obesity
  • Focus First in man; Therapeutic Use
  • Sponsors NGM Biopharmaceuticals
  • Most Recent Events

    • 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Jun 2016 Data from the trial are expected in 2017, according to an NGM Biopharmaceuticals media release.
    • 17 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top